Navigen's board of directors elected Brandi to be chief executive officer effective April 2014. She was Navigen's first official employee, and from 2007 until her promotion to CEO she served as chief business officer of the company. Prior to joining Navigen, she held senior positions in business development, corporate strategy, and investor relations at NPS Pharmaceuticals, where she negotiated and closed multiple licensing transactions and led the company's portfolio review and strategic decision-making processes. In her last year at NPS, she also served as the head of investor relations.
Prior to joining NPS, Brandi was director of business development at Emergen, a Utah genetics start-up. She was also a life sciences management consultant at Booz Allen & Hamilton, where she advised clients on a variety of business and strategic issues including mergers and acquisitions, post-merger integration and development of new business ventures. She began her career as an investment banking analyst at Merrill Lynch, where she worked on multiple public debt and equity financing transactions, structured financings, and mergers and acquisitions.
Brandi graduated summa cum laude from the University of Utah with an honors degree in Finance. She earned an MBA degree at Stanford University's Graduate School of Business.
ABOUT NAVIGENCreating a New Class of Drugs
Navigen is a drug discovery and development company developing an important new class of therapies to improve and save lives. The company was founded by a team of industry veterans with a history of successfully advancing novel therapeutics. Navigen is leveraging its unparalleled experience working with D-peptides to bring forward a range of promising development programs with the potential to address many critical areas of unmet medical need.
Building on landmark discoveries made at leading medical research institutions including the University of Utah, we have developed a discovery platform that harnesses the full potential of D-peptides as drugs with superior targeting and specificity and with limited or no risk of antigenicity. Navigen has a suite of proprietary tools at its disposal to access more (larger) targets and to shorten the required time it takes to identify promising new drugs.
Our lead product, CPT31, is in development for treatment and prevention of HIV. We plan to initiate human studies with CPT31 in the first quarter of 2019. We are also developing a D-peptide for cancer immunotherapy that targets SIRPα, an innate checkpoint inhibitor and a D-peptide anti-TNF that we expect to have significant delivery and antigenicity advantages over current biologics. We are also developing a D-peptide anti-TNF that we expect to have significant delivery and antigenicity advantages over current biologics. We will continue to build our internal pipeline and will also enter into collaborations to discover new D-peptides for targets of interest. We welcome inquiries related to partnering including R&D collaborations and licensing.
Our PeopleMeet the Navigen Team
Navigen chief executive officer Brandi Simpson, MBA, vice president of research Alan Mueller, PhD, and sr. director of pre-clinical development Daniel Wettstein, MD, PhD, have over 60 years of combined experience in bringing forward biomedical technologies in both private and public company settings.